Publication Name	World Journal of Gastroenterology
Manuscript ID	5491
Country	China

Received	2013-09-11 08:48
Peer-Review Started	2013-09-13 09:53
First Decision by Editorial Office Director
Return for Revision	2013-10-30 11:29
Revised	2013-11-21 18:40
Publication Fee Transferred
Second Decision by Editor	2014-01-05 14:51
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-01-05 15:25
Articles in Press
Edit the Manuscript by Language Editor	2014-03-12 13:33
Typeset the Manuscript	2014-03-21 12:47
Publish the Manuscript Online	2014-04-14 10:49

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection
Manuscript Source	Invited Manuscript
All Author List	Kai-Li Wang, Han-Qian Xing, Hong Zhao, Jun-Wei Liu, Deng-Lian Gao, Xue-Hua Zhang, Hong-Yu Yao, Li Yan and Jun Zhao
Funding Agency and Grant Number
Corresponding Author	Jun Zhao, Professor, Department of Blood Purification, 302 Hospital of the People’s Liberation Army, Xisihuan Zhonglu No. 100, Fengtai District, Beijing 100039, China. zhj68@263.net
Key Words	Chronic hepatitis C; End-stage renal disease; Hemodialysis; Hepatitis C virus; Peginterferon
Core Tip	The most appropriate treatment for hepatitis C virus (HCV)-positive hemodialysis patients is unknown, and the available treatments have only been assessed in a limited manner. Therefore, this study evaluated the efficacy and tolerability of treatment with low-dose standard or pegylated interferon (PEG-IFN) in HCV-positive hemodialysis patients. The results of the study indicated that low-dose interferon monotherapy, either PEG-IFNα-2a or standard interferon α-2b, is an effective treatment option for HCV-positive hemodialysis patients. Anemia was the most frequently encountered adverse event, but this could be managed with erythropoietin. These results provide important information for clinicians faced with these treatment decisions.
Publish Date	2014-04-14 10:49
Citation	Wang KL, Xing HQ, Zhao H, Liu JW, Gao DL, Zhang XH, Yao HY, Yan L, Zhao J. Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection. World J Gastroenterol 2014; 20(14): 4071-4075
URL	http://www.wjgnet.com/1007-9327/full/v20/i14/4071.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i14.4071

Full Article (PDF)	WJG-20-4071.pdf
Full Article (Word)	WJG-20-4071.doc
Manuscript File	5491-Review.doc
Answering Reviewers	5491-Answering reviewers.pdf
Copyright License Agreement	5491-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5491-Language certificate.pdf
Peer-review Report	5491-Peer reviews.pdf
Scientific Editor Work List	5491-Scientific editor work list.doc